Palonosetron is a potent 5-HT 3 receptor antagonist with a unique structure and some unusual properties. Here we explore the properties of palonosetron at heterologously expressed 5-HT 3 A and 5-HT 3 AB receptors. We used receptors expressed in HEK293 cells, and functionally analysed them using a membrane potential sensitive dye in a Flexstation, which revealed IC 50 s of 0.24 nM and 0.18 nM for 5-HT 3 A and 5-HT 3 AB receptors respectively. Radioligand binding studies with [
Introduction

5-HT
receptors are members of the Cys-loop family of ligandgated ion channels, membrane proteins that are responsible for fast excitatory and inhibitory synaptic neurotransmission in central and peripheral nervous systems, and the targets for a number of important therapeutics. 5-HT 3 receptor antagonists are routinely used in the management of post-operative, radiotherapy-induced and chemotherapy-induced nausea and vomiting and for treating irritable bowel syndrome in patients that do not respond adequately to conventional therapies. A range of other therapeutic applications has also been suggested (reviewed in (Thompson and Lummis, 2007; Walstab et al., 2010) ). Antagonists are often referred to as the "setrons", and include ondansetron, granisetron and palonosetron (Fig. 1 ). These drugs are potent (K d ¼ nM À pM), long lived in vivo, and most are highly selective for the 5-HT 3 receptor. Furthermore, they are usually well tolerated and display only mild, transient side-effects, making them the preferred choice of drug in most instances (Aapro, 2004; Blower, 1995; Eglen et al., 1995; Hirata et al., 2007) .
Palonosetron has a different structure from the other 5-HT 3 antagonists (Fig. 1) , and some distinctive properties. The first published accounts of these properties were in 1995, when radioligand binding experiments demonstrated that it bound to 5-HT 3 receptors with high potency and selectivity, and in vivo data showed an anti-emetic efficacy greater than or equal to that of ondansetron or granisetron Eglen et al., 1995; Wong et al., 1995) . At that time, however, it was not clear that there are multiple 5-HT 3 receptor subunits, (A-E), in addition to alternative splice variants, thus providing the potential for a wide range of different 5-HT 3 receptor subtypes. Heteromeric assemblies of 5-HT3A plus 5-HT3C, 5-HT3D or 5-HT3E subunits have not yet been extensively studied, but their biophysical properties appear similar to homomeric 5-HT 3 A receptors (see (Niesler, 2011) and (Walstab et al., 2010 ) for reviews). 5-HT 3 AB receptors, however, have been extensively investigated in heterologous systems, and have differing concentrationeresponse curves (increased EC 50 values and shallower Hill slopes), increased single channel conductance (5-HT 3 A ¼ sub-pS; 5-HT 3 AB ¼ 16e30 pS), an increased rate of desensitisation, reduced Ca 2þ permeability and a non-linear currentevoltage relationship (Davies et al., 1999; Kelley et al., 2003;  Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); HEK, human embryonic kidney; IC 50 , concentration of antagonist required for half-maximal inhibition; K d , affinity constant. Livesey et al., 2008) . To determine if there are differences in the affinity and association and dissociation rates of palonosetron in 5-HT 3 A and 5-HT 3 AB receptors, we here explore the effects of palonosetron on 5-HT 3 receptor function and binding in these receptor subtypes.
Materials and methods
Materials
All cell culture reagents were obtained from Gibco BRL (Paisley, U.K.), except foetal calf serum which was from Labtech International (Ringmer, U.K. (Lugano, Switzerland) , and both this and the unlabelled form of palonosetron were kindly gifted by Helsinn Healthcare (Lugano, Switzerland). All other reagents were of the highest obtainable grade.
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained on 90 mm tissue culture plates at 37 C and 7% CO 2 in a humidified atmosphere. They were cultured in DMEM:F12 (Dulbecco's Modified Eagle Medium/Nutrient Mix F12 (1:1)) with GlutaMAXÔ I media containing 10% foetal calf serum and passaged when confluent. For radioligand binding studies cells in 90 mm dishes were transfected using PEI and incubated for 3e4 days before use. For functional studies cells were plated on 96 well plates, transfected using the Neon transfection system (Invitrogen) and incubated 1e2 days before assay. Mutagenesis reactions were performed using QuikChange (Agilent Technologies Inc., CA, USA) using human 5-HT 3A or 5-HT 3B receptor subunit cDNA (accession numbers: P46098 or O95264) in pcDNA3.1 (Invitrogen, Paisley, UK). Subunit numberings have been altered to the aligning residues in the mouse 5-HT 3 A receptor.
Radioligand binding
Methods were as previously described (Lummis et al., 1993) respectively at 4 C. Dissociation was initiated with unlabelled ligands to give a final concentrations of 100 mM (5-HT), 10 mM (quipazine), 1 mM (MDL72222) or 100 nM (palonosetron). All samples were terminated by vacuum filtration using a Brandel cell harvester onto GF/B filters pre-soaked in 0.3% polyethyleneimine. Radioactivity was determined by scintillation counting using a Beckman LS6000SC (Fullerton, California, USA).
Fluorescent studies
These were performed as previously described (Price and Lummis, 2005) . Briefly, cells were gently rinsed twice with buffer (10 mM HEPES, 115 mM NaCl, 1 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, pH 7.4) and 100 ml fluorescent membrane-potential sensitive dye (Molecular Devices) added. Cells were then incubated at room temperature for 45 min before assay. For inhibition studies, palonesetron was added either with the dye, ensuring a 45 min pre-incubation, or simultaneously with 5-HT (co-application). Fluorescence was measured in a FLEXstationÔ (Molecular Devices Ltd., Wokingham, UK) every 2 s for 200 s using the acquisition software SOFTmax Ò PRO v4.3. Control (buffer alone) or 5-HT (0.001 mMe 30 mM) was added to each well at 20 s. Typical responses are shown in Fig. 2. 
Data analysis
Data were analysed by iterative curve fitting using Prism software (GraphPad, San Diego, California, USA). Determination of K i values was performed using the ChengePrusoff equation. Values are presented as mean AE SEM, n ¼ 3e6.
Results
Functional studies
Examination of palonosetron inhibition of 5-HT 3 receptors expressed in oocytes revealed very slow recovery after washout, with <10% of the original response being recovered after a 10 min wash (data not shown). We therefore determined the inhibitory effects of palonosetron on 5-HT-induced responses using 5-HT 3 receptors expressed in HEK293 cells loaded with membrane sensitive fluorescent dye where washout is not required. Preliminary experiments revealed palonosetron required at least 5 min incubation before application of 5-HT to reveal its full inhibition, and thereafter it was preincubated for 45 min. Data revealed different apparent potencies of palonosetron at 5-HT 3 A receptors, depending upon whether it was preincubated (pIC 50 ¼ 9.73 AE 0 0.13; IC 50 ¼ 0.18 nM, n ¼ 4) or co-applied with 5-HT (pIC 50 ¼ 7.08 AE 0.14; IC 50 ¼ 83 nM, n ¼ 4), suggesting that palonosetron has a relatively slow on rate, and in particular that its on rate is slower than that of 5-HT (Fig. 3A) . With a 45 min preincubation, palonosetron inhibition of 5-HTinduced responses (Fig. 3B ) revealed sub-nanomolar IC 50 s at both 5-HT 3 A and 5-HT 3 AB receptors: pIC 50 ¼ 9.61 AE 0.13; (IC 50 ¼ 0.24 nM), and 9.73 AE 0.27; (IC 50 ¼ 0.18 nM) respectively (n ¼ 4).
Examination of 5-HT concentration response curves in the presence of 0, 0.1 nM or 0.3 nM palonosetron revealed increased EC 50 s and decreased maximal responses with increasing palonosetron concentrations (Fig. 4) . . This is slower than previously reported where association was complete in under 10 min . Our dissociation rates were also slower than previously reported, and were also strongly dependent on the ligand used for dissociation. An excess of unlabelled palonosetron gave t 1/2 values for dissociation of 1.5 h and 1.0 h for 5-HT 3 A and 5-HT 3 AB receptors respectively, with values of 2.3 h and 1.7 h when an excess of MDL72222 was used. However when the agonists 5-HT or quipazine were used, t 1/2 values were >10 h. Data are shown in Table 1 with example curves in Fig. 5 . These reveal that in the presence of agonists specific binding does not approach background levels until 2e5 days after dissociation is initiated. Similar experiments using [ 3 H]granisetron revealed no differences in rates using agonists or antagonists (Table 1 and Fig. 6 ).
Radioliogand binding
Discussion
Palonosetron is a potent 5-HT 3 receptor antagonist which is proving to be superior to other 5-HT 3 receptor antagonists for the treatment of acute and delayed post-operative, radiotherapyinduced and chemotherapy-induced nausea and vomiting. The unusual properties of palonosetron, which have been proposed to explain its superiority, include allosteric interactions, positive cooperativity and palonosetron-triggered 5-HT 3 receptor internalization (Rojas et al., 2008 (Rojas et al., , 2010 . Internalization was not explored in our association and dissociation rate experiments, as this process would not occur at the temperatures at which these experiments were performed, but the slow palonosetron dissociation rate shown here could provide an additional or alternative explanation to internalization: our data show palonosetron has the ability to inhibit 5-HT 3 receptors for considerably longer than the more established 5-HT 3 receptor antagonists such as ondansetron and granisetron, which could result in a prolonged anti-emetic behaviour.
Palonosetron is a potent inhibitor of 5-HT-induced increases in fluorescence of a membrane potential sensitive dye. Inhibition of 5-HT 3 receptor function at low concentrations was expected as palonosetron has an affinity for 5-HT 3 receptors that is greater than other commonly used 5-HT 3 receptor antagonists (e.g. NG108-15 cells K d ¼ 0.05 nM , human hippocampus K d ¼ 0.15 nM , transfected HEK293 cells (Rojas et al., 2008) ). The slow dissociation rates we observed (t 1/2 ¼ 1e22 h) differ from previous studies (t ½ ¼ 8e 10 min) , but are consistent with the slow recovery from palonosetron-induced 5-HT 3 receptor inhibition we observed in our preliminary experiments in oocytes, which precluded us from using them in this study. Somewhat similar data were observed by Rojas et al. (2008) after a 60 min wash, but only 2% remaining in a cell-free membrane preparation (Rojas et al., 2010) . Our preparation is similar to their cell free preparation, (i.e. it does not contain whole cells) although it is not washed as extensively, and our cells were not treated with trypsin; thus it may be that the different procedures can significantly effect binding characteristics. We did not observe any major difference between the effects of palonosetron at homomeric (5-HT 3 A) and heteromeric (5-HT 3 AB) receptors. 5-HT 3 A receptors may predominate in the CNS, while 5-HT 3 AB receptors may be more abundant in the PNS. Nevertheless, both 5-HT3A and 5-HT3B subunits, and indeed the other three subunits in this family (5-HT3Ce5-HT3E), are widely distributed in ]palonosetron using HEK293 cells expressing 5-HT 3 A and 5-HT 3 AB receptors. Association was rapid for both 5-HT 3 A and 5-HT 3 AB receptors, with maximal levels being reached within 30 min. Dissociation rates were slower, although were faster with antagonists (MDL72222, palonosetron) than agonists (quipazine). Parameters derived from these data are given in Section 3.3. many body regions (Holbrook et al., 2009; Niesler, 2011) . Our data indicate similar palonosetron K d s at 5-HT 3 A and 5-HT 3 AB receptors, consistent with previous work showing that competitive antagonists (with one exception, see below) do not show major differences in potency between these two receptor subtypes. This is because the binding site for these compounds is located between two 5-HT 3 A subunits, which assemble as part of the 5-HT 3 AB pentamer (Lochner and Lummis, 2010; Thompson et al., 2011) . The only competitive antagonist that has been identified with distinct affinities at 5-HT 3 A and 5-HT 3 AB receptors is VUF10166, and the different in affinities is due to an allosteric binding site at an A þ Binterface (Thompson et al., 2012 ). An allosteric mechanism has also been previously suggested for palonosetron (Moura Barbosa et al., 2010) using computational data, and allosteric binding characteristics have been reported (concave Scatchard plots and Hill slopes of 1.5 (Rojas et al., 2008) . Our data showing increased EC 50 s and decreased maximal responses with increasing concentrations of palonosetron are consistent with a non-competitive mode of action of this compound, i.e. action at an allosteric site. However they are also consistent with an irreversible competitive antagonist, and, given the slow off rates of [ 3 H]palonosetron, we consider this is the correct interpretation, and that these data reflect the fact that palonosetron does not significantly dissociate from the receptor during these experiments. We did observe a difference in [ 3 H]palonosetron dissociation rates depending on the unlabelled ligand used for displacement, with antagonists resulting in more rapid dissociation compared to agonists; similar findings have been previously observed for native 5-HT 3 receptors in NG108-15 cells, and 5-HT 3 A receptors in HEK293 cells . These authors suggest that binding of agonists to unoccupied binding sites can increase the receptors affinity for prebound ligands and thereby slow their dissociation. We propose there is a similar mechanism in our experiments. At the start of the dissociation experiments up to five potential binding sites could be occupied by [ 3 H]palonosetron in 5-HT 3 A receptors, with less (1e3) in 5-HT 3 AB receptors. Subsequent occupancy of a binding site by unlabelled palonosetron or another competitive antagonist such as MDL72222 would not alter the state of the receptor, while agonist binding likely causes entry into a high affinity desensitized state. Palonosetron, in one or more of the remaining binding sites, would then only dissociate slowly. Our data also show that both association and dissociation rates are slightly faster for 5-HT 3 AB receptors, which may be due to subtle difference in structure of this receptor; it is known, for example, that these receptors are more prone to spontaneous opening (Hu and Peoples, 2008) . Our data reveal that agonists have a similar effect in homomeric and heteromeric receptors, providing evidence that there is more than one orthosteric (A þ A-) binding site in heteromeric receptors.
In conclusion we have shown that palonosetron binds with similar affinities at 5-HT 3 A and 5-HT 3 AB receptors. We observed that in both receptor subtypes there is slow dissociation of [ 3 H]palonosetron, and its rate is ligand-dependent. This slow dissociation, which is particularly pronounced in the presence of agonists, provides a possible additional or alternative explanation for the long lasting therapeutic effects of palonosetron. Our conclusions are strongly supported by a study published during revision of this manuscript (Hothersall et al., 2013 
